BRIEF—Angelini co-leads $21 million series A for Neumirna

Angelini Ventures, the investment arm of Angelini Industries, has co-led a 20 million euro ($21 million) series A funding round for Neumirna Therapeutics, an RNA-focused biotech established in 2020.

The Danish firm aims to develop treatments for neurological disorders like drug-resistant epilepsy and Parkinson's disease using microRNA-based therapies.

The funding will enable Neumirna to advance its lead epilepsy candidate NMT.001 into clinical trials and expand its R&D capabilities while scaling its RNA drug development platform.

Chief executive Janine Erler said the funding, which is Angelini Ventures' fifth neuroscience-focused investment, was vital for bringing NMT.001 to clinical validation.